Skip to main content
. 2013 Apr 9;8(4):e61338. doi: 10.1371/journal.pone.0061338

Figure 4. Adoptive transfer of CD19 CAR-targeted T cells into mice with leukemia.

Figure 4

(a) Flow cytometry of bulk mouse T splenocytes double-transduced with GL-2A-m1928z. (b) Survival curve of mice injected with Eμ-ALL01 and not treated (No Rx), treated only with cyclophosphamide (CTX), or treated with cyclophosphamide (100-200 mg/kg IP) and CD19 CAR-targeted T cells (CTX+m1928z), displayed in (a). This data (n = 28) is pooled from 2 independent experiments. Another study (Supplemental Figure S2) confirms that cyclophosphamide and control T cells mediate no survival advantage. (c) Flow cytometry of cells from the BM, spleen (SP), and lymph node (LN) of a single mouse treated with cyclophosphamide but sacrificed due to clinical deterioration. Splenocytes were also stained with isotype antibodies (ISO) as a control.